S-1/A: Applied DNA Sciences Eyes $10 Million Boost with Unit Offering

Applied DNA Sciences is seeking to raise up to $10 million through the sale of units, each containing common stock or pre-funded warrants, and Series A and B warrants.

Summary

• Applied DNA Sciences is offering 3,984,064 units, each consisting of one share of common stock (or a pre-funded warrant), one Series A warrant, and one Series B warrant, at an assumed price of $2.51 per unit.
• The company is also offering placement agent warrants to purchase up to 199,203 shares of common stock.
• The Series A warrants are immediately exercisable at an exercise price of $ per share and expire five years from the closing date, while Series B warrants are immediately exercisable at an exercise price of $ per share and expire one year from the closing date.
• The offering will terminate on June 30, 2024, and there is no minimum number of securities or aggregate amount of proceeds required as a condition of closing.
• Net proceeds from the offering are estimated to be $8.97 million, which will be used for the further development of Therapeutic DNA Production and MDx Testing Services, as well as general corporate purposes.
• The company has received a deficiency letter from Nasdaq for not meeting the minimum stockholders' equity requirement and must submit a compliance plan by July 1, 2024.
• A reverse stock split at a ratio of one-for-twenty shares was effected on April 25, 2024, to regain compliance with Nasdaq's minimum bid price requirement.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is actively seeking funding and has regained compliance with Nasdaq's minimum bid price requirement, it faces significant financial challenges, including recurring net losses, substantial accumulated deficit, and doubt about its ability to continue as a going concern. The offering itself introduces dilution risks for investors.

Positives

• The offering aims to raise capital for the development of key services.
• The company has regained compliance with Nasdaq's minimum bid price requirement.
• The company has broad discretion in the application of the net proceeds from this offering.

Negatives

• There is no minimum amount of securities required to be sold, and the company may not raise the amount of capital it believes is required for its business plans.
• The company has received a deficiency letter from Nasdaq for not meeting the minimum stockholders' equity requirement.
• The company has recurring net losses, which have resulted in an accumulated deficit of $308,255,808 as of March 31, 2024.
• The company has incurred a net loss of $5,624,064 for the six months ended March 31, 2024.
• At March 31, 2024, the company had cash and cash equivalents of $3,149,640.
• There is substantial doubt relating to the company's ability to continue as a going concern.

Risks

• The company may not raise the required capital, impacting its business plans.
• Failure to comply with Nasdaq's equity requirement could lead to delisting.
• The company faces risks related to its business, including limited revenue and dependence on regulatory approval.
• The reverse stock split may adversely impact the market price of the common stock.
• The company may be required to repurchase certain of its warrants.
• The Series Warrants may not have any value.
• If the Series A Warrants are exercised by way of an alternative cashless exercise, investors may suffer substantial dilution
• The company will likely not receive any additional funds upon the exercise of the Series A Warrants.
• Certain beneficial provisions in the Series Warrants will not be effective until the company is able to receive stockholder approval of such provisions, and if the company is unable to obtain such approval the Warrant will have significantly less value.
• If the FDA implements its plans to regulate LDTs, the company could incur substantial costs and delays associated with trying to obtain pre-market clearance or approval and costs associated with complying with post-market requirements.

Future Outlook

The company intends to use the net proceeds from the sale of the securities for the further development of its Therapeutic DNA Production and MDx Testing Services, as well as general corporate purposes, which may include research and development expenses, capital expenditures, working capital and general and administrative expenses, and potential acquisitions of or investments in businesses, products and technologies that complement its business.

Industry Context

The company is positioning itself to capitalize on the rapid growth of mRNA therapies and the increasing demand for DNA manufacturing services.

Stakeholder Impact

• Shareholders face potential dilution from the offering and risks related to the company's financial stability.
• Employees' job security is tied to the company's ability to secure funding and execute its business plan.
• Customers may be affected by the company's ability to invest in and develop its services.
• Suppliers and creditors face risks related to the company's financial stability and ability to meet its obligations.

Next Steps

• The company must submit a compliance plan to Nasdaq by July 1, 2024, to address the minimum stockholders' equity requirement.
• The company intends to hold a special meeting of shareholders to obtain Stockholder Approval, with the recommendation of the Companys Board of Directors that such proposal be approved, and the Company shall solicit proxies from its shareholders in connection therewith in the same manner as all other management proposals in such proxy statement and all management-appointed proxyholders shall vote their proxies in favor of such proposal.
• The company will use the net proceeds from the offering for the further development of its Therapeutic DNA Production and MDx Testing Services, as well as general corporate purposes.

Key Dates

Keywords

Units, Warrants, Offering, Common Stock, Therapeutic DNA Production, MDx Testing Services, Reverse Stock Split, Nasdaq, Pre-Funded Warrants, Series A Warrants, Series B Warrants, Placement Agent Warrants